The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Human EGF Market Research Report 2025
Synopsis
Human EGF is a 6-kDa protein with 53 amino acid residues and three intramolecular disulfide bonds. EGF binds to the epidermal growth factor receptor. Initially, human EGF was known as urogastrone.
This report studies the Recombinant Human EGF (Epidermal Growth Factor) obtained by recombinant protein.
The global Recombinant Human EGF market was valued at US$ 10300 million in 2023 and is anticipated to reach US$ 19500 million by 2030, witnessing a CAGR of 9.5% during the forecast period 2024-2030.
EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface.
This stimulates ligand-induced dimerization, activating the intrinsic protein-tyrosine kinase activity of the receptor.
The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell – a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR – that ultimately lead to DNA synthesis and cell proliferation.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human EGF, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human EGF.
Report Scope
The Recombinant Human EGF market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human EGF market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human EGF companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
FUJIFILM Irvine Scientific
PeproTech, Inc
R&D Systems (Bio-Techne)
Miltenyi Biotec
Thermo Fisher Scientific
Abcam PLC
BioLegend Way
STEMCELL Technologies
Eurofins DiscoverX
RayBiotech, Inc
Prospec-Tany
Tonbo Biosciences
EnQuire Bio
ScienCell Research Laboratories
BioVision, Inc
Abm Inc
Cell Guidance Systems
Creative BioMart
Sino Biological
Cell Sciences
Axol Bioscience
Segment by Type
≥98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
Segment by Application
Scientific Research
Medical Drug
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Human EGF companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Human EGF is a 6-kDa protein with 53 amino acid residues and three intramolecular disulfide bonds. EGF binds to the epidermal growth factor receptor. Initially, human EGF was known as urogastrone.
This report studies the Recombinant Human EGF (Epidermal Growth Factor) obtained by recombinant protein.
The global Recombinant Human EGF market was valued at US$ 10300 million in 2023 and is anticipated to reach US$ 19500 million by 2030, witnessing a CAGR of 9.5% during the forecast period 2024-2030.
EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface.
This stimulates ligand-induced dimerization, activating the intrinsic protein-tyrosine kinase activity of the receptor.
The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell – a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR – that ultimately lead to DNA synthesis and cell proliferation.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human EGF, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human EGF.
Report Scope
The Recombinant Human EGF market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human EGF market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human EGF companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
FUJIFILM Irvine Scientific
PeproTech, Inc
R&D Systems (Bio-Techne)
Miltenyi Biotec
Thermo Fisher Scientific
Abcam PLC
BioLegend Way
STEMCELL Technologies
Eurofins DiscoverX
RayBiotech, Inc
Prospec-Tany
Tonbo Biosciences
EnQuire Bio
ScienCell Research Laboratories
BioVision, Inc
Abm Inc
Cell Guidance Systems
Creative BioMart
Sino Biological
Cell Sciences
Axol Bioscience
Segment by Type
≥98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE
Segment by Application
Scientific Research
Medical Drug
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Human EGF companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Human EGF Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ≥98% SDS-PAGE
1.2.3 95%-98% SDS-PAGE
1.2.4 <95% SDS-PAGE
1.3 Market by Application
1.3.1 Global Recombinant Human EGF Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Scientific Research
1.3.3 Medical Drug
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Human EGF Market Perspective (2019-2030)
2.2 Recombinant Human EGF Growth Trends by Region
2.2.1 Global Recombinant Human EGF Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recombinant Human EGF Historic Market Size by Region (2019-2024)
2.2.3 Recombinant Human EGF Forecasted Market Size by Region (2025-2030)
2.3 Recombinant Human EGF Market Dynamics
2.3.1 Recombinant Human EGF Industry Trends
2.3.2 Recombinant Human EGF Market Drivers
2.3.3 Recombinant Human EGF Market Challenges
2.3.4 Recombinant Human EGF Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Human EGF Players by Revenue
3.1.1 Global Top Recombinant Human EGF Players by Revenue (2019-2024)
3.1.2 Global Recombinant Human EGF Revenue Market Share by Players (2019-2024)
3.2 Global Recombinant Human EGF Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Human EGF Revenue
3.4 Global Recombinant Human EGF Market Concentration Ratio
3.4.1 Global Recombinant Human EGF Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Human EGF Revenue in 2023
3.5 Recombinant Human EGF Key Players Head office and Area Served
3.6 Key Players Recombinant Human EGF Product Solution and Service
3.7 Date of Enter into Recombinant Human EGF Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Human EGF Breakdown Data by Type
4.1 Global Recombinant Human EGF Historic Market Size by Type (2019-2024)
4.2 Global Recombinant Human EGF Forecasted Market Size by Type (2025-2030)
5 Recombinant Human EGF Breakdown Data by Application
5.1 Global Recombinant Human EGF Historic Market Size by Application (2019-2024)
5.2 Global Recombinant Human EGF Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Recombinant Human EGF Market Size (2019-2030)
6.2 North America Recombinant Human EGF Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recombinant Human EGF Market Size by Country (2019-2024)
6.4 North America Recombinant Human EGF Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Human EGF Market Size (2019-2030)
7.2 Europe Recombinant Human EGF Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recombinant Human EGF Market Size by Country (2019-2024)
7.4 Europe Recombinant Human EGF Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Human EGF Market Size (2019-2030)
8.2 Asia-Pacific Recombinant Human EGF Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recombinant Human EGF Market Size by Region (2019-2024)
8.4 Asia-Pacific Recombinant Human EGF Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Human EGF Market Size (2019-2030)
9.2 Latin America Recombinant Human EGF Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recombinant Human EGF Market Size by Country (2019-2024)
9.4 Latin America Recombinant Human EGF Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Human EGF Market Size (2019-2030)
10.2 Middle East & Africa Recombinant Human EGF Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recombinant Human EGF Market Size by Country (2019-2024)
10.4 Middle East & Africa Recombinant Human EGF Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 FUJIFILM Irvine Scientific
11.1.1 FUJIFILM Irvine Scientific Company Detail
11.1.2 FUJIFILM Irvine Scientific Business Overview
11.1.3 FUJIFILM Irvine Scientific Recombinant Human EGF Introduction
11.1.4 FUJIFILM Irvine Scientific Revenue in Recombinant Human EGF Business (2019-2024)
11.1.5 FUJIFILM Irvine Scientific Recent Development
11.2 PeproTech, Inc
11.2.1 PeproTech, Inc Company Detail
11.2.2 PeproTech, Inc Business Overview
11.2.3 PeproTech, Inc Recombinant Human EGF Introduction
11.2.4 PeproTech, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.2.5 PeproTech, Inc Recent Development
11.3 R&D Systems (Bio-Techne)
11.3.1 R&D Systems (Bio-Techne) Company Detail
11.3.2 R&D Systems (Bio-Techne) Business Overview
11.3.3 R&D Systems (Bio-Techne) Recombinant Human EGF Introduction
11.3.4 R&D Systems (Bio-Techne) Revenue in Recombinant Human EGF Business (2019-2024)
11.3.5 R&D Systems (Bio-Techne) Recent Development
11.4 Miltenyi Biotec
11.4.1 Miltenyi Biotec Company Detail
11.4.2 Miltenyi Biotec Business Overview
11.4.3 Miltenyi Biotec Recombinant Human EGF Introduction
11.4.4 Miltenyi Biotec Revenue in Recombinant Human EGF Business (2019-2024)
11.4.5 Miltenyi Biotec Recent Development
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Company Detail
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Recombinant Human EGF Introduction
11.5.4 Thermo Fisher Scientific Revenue in Recombinant Human EGF Business (2019-2024)
11.5.5 Thermo Fisher Scientific Recent Development
11.6 Abcam PLC
11.6.1 Abcam PLC Company Detail
11.6.2 Abcam PLC Business Overview
11.6.3 Abcam PLC Recombinant Human EGF Introduction
11.6.4 Abcam PLC Revenue in Recombinant Human EGF Business (2019-2024)
11.6.5 Abcam PLC Recent Development
11.7 BioLegend Way
11.7.1 BioLegend Way Company Detail
11.7.2 BioLegend Way Business Overview
11.7.3 BioLegend Way Recombinant Human EGF Introduction
11.7.4 BioLegend Way Revenue in Recombinant Human EGF Business (2019-2024)
11.7.5 BioLegend Way Recent Development
11.8 STEMCELL Technologies
11.8.1 STEMCELL Technologies Company Detail
11.8.2 STEMCELL Technologies Business Overview
11.8.3 STEMCELL Technologies Recombinant Human EGF Introduction
11.8.4 STEMCELL Technologies Revenue in Recombinant Human EGF Business (2019-2024)
11.8.5 STEMCELL Technologies Recent Development
11.9 Eurofins DiscoverX
11.9.1 Eurofins DiscoverX Company Detail
11.9.2 Eurofins DiscoverX Business Overview
11.9.3 Eurofins DiscoverX Recombinant Human EGF Introduction
11.9.4 Eurofins DiscoverX Revenue in Recombinant Human EGF Business (2019-2024)
11.9.5 Eurofins DiscoverX Recent Development
11.10 RayBiotech, Inc
11.10.1 RayBiotech, Inc Company Detail
11.10.2 RayBiotech, Inc Business Overview
11.10.3 RayBiotech, Inc Recombinant Human EGF Introduction
11.10.4 RayBiotech, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.10.5 RayBiotech, Inc Recent Development
11.11 Prospec-Tany
11.11.1 Prospec-Tany Company Detail
11.11.2 Prospec-Tany Business Overview
11.11.3 Prospec-Tany Recombinant Human EGF Introduction
11.11.4 Prospec-Tany Revenue in Recombinant Human EGF Business (2019-2024)
11.11.5 Prospec-Tany Recent Development
11.12 Tonbo Biosciences
11.12.1 Tonbo Biosciences Company Detail
11.12.2 Tonbo Biosciences Business Overview
11.12.3 Tonbo Biosciences Recombinant Human EGF Introduction
11.12.4 Tonbo Biosciences Revenue in Recombinant Human EGF Business (2019-2024)
11.12.5 Tonbo Biosciences Recent Development
11.13 EnQuire Bio
11.13.1 EnQuire Bio Company Detail
11.13.2 EnQuire Bio Business Overview
11.13.3 EnQuire Bio Recombinant Human EGF Introduction
11.13.4 EnQuire Bio Revenue in Recombinant Human EGF Business (2019-2024)
11.13.5 EnQuire Bio Recent Development
11.14 ScienCell Research Laboratories
11.14.1 ScienCell Research Laboratories Company Detail
11.14.2 ScienCell Research Laboratories Business Overview
11.14.3 ScienCell Research Laboratories Recombinant Human EGF Introduction
11.14.4 ScienCell Research Laboratories Revenue in Recombinant Human EGF Business (2019-2024)
11.14.5 ScienCell Research Laboratories Recent Development
11.15 BioVision, Inc
11.15.1 BioVision, Inc Company Detail
11.15.2 BioVision, Inc Business Overview
11.15.3 BioVision, Inc Recombinant Human EGF Introduction
11.15.4 BioVision, Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.15.5 BioVision, Inc Recent Development
11.16 Abm Inc
11.16.1 Abm Inc Company Detail
11.16.2 Abm Inc Business Overview
11.16.3 Abm Inc Recombinant Human EGF Introduction
11.16.4 Abm Inc Revenue in Recombinant Human EGF Business (2019-2024)
11.16.5 Abm Inc Recent Development
11.17 Cell Guidance Systems
11.17.1 Cell Guidance Systems Company Detail
11.17.2 Cell Guidance Systems Business Overview
11.17.3 Cell Guidance Systems Recombinant Human EGF Introduction
11.17.4 Cell Guidance Systems Revenue in Recombinant Human EGF Business (2019-2024)
11.17.5 Cell Guidance Systems Recent Development
11.18 Creative BioMart
11.18.1 Creative BioMart Company Detail
11.18.2 Creative BioMart Business Overview
11.18.3 Creative BioMart Recombinant Human EGF Introduction
11.18.4 Creative BioMart Revenue in Recombinant Human EGF Business (2019-2024)
11.18.5 Creative BioMart Recent Development
11.19 Sino Biological
11.19.1 Sino Biological Company Detail
11.19.2 Sino Biological Business Overview
11.19.3 Sino Biological Recombinant Human EGF Introduction
11.19.4 Sino Biological Revenue in Recombinant Human EGF Business (2019-2024)
11.19.5 Sino Biological Recent Development
11.20 Cell Sciences
11.20.1 Cell Sciences Company Detail
11.20.2 Cell Sciences Business Overview
11.20.3 Cell Sciences Recombinant Human EGF Introduction
11.20.4 Cell Sciences Revenue in Recombinant Human EGF Business (2019-2024)
11.20.5 Cell Sciences Recent Development
11.21 Axol Bioscience
11.21.1 Axol Bioscience Company Detail
11.21.2 Axol Bioscience Business Overview
11.21.3 Axol Bioscience Recombinant Human EGF Introduction
11.21.4 Axol Bioscience Revenue in Recombinant Human EGF Business (2019-2024)
11.21.5 Axol Bioscience Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Recombinant Human EGF Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of ≥98% SDS-PAGE
Table 3. Key Players of 95%-98% SDS-PAGE
Table 4. Key Players of <95% SDS-PAGE
Table 5. Global Recombinant Human EGF Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Recombinant Human EGF Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Recombinant Human EGF Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Recombinant Human EGF Market Share by Region (2019-2024)
Table 9. Global Recombinant Human EGF Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Recombinant Human EGF Market Share by Region (2025-2030)
Table 11. Recombinant Human EGF Market Trends
Table 12. Recombinant Human EGF Market Drivers
Table 13. Recombinant Human EGF Market Challenges
Table 14. Recombinant Human EGF Market Restraints
Table 15. Global Recombinant Human EGF Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Recombinant Human EGF Market Share by Players (2019-2024)
Table 17. Global Top Recombinant Human EGF Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human EGF as of 2023)
Table 18. Ranking of Global Top Recombinant Human EGF Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Recombinant Human EGF Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Recombinant Human EGF Product Solution and Service
Table 22. Date of Enter into Recombinant Human EGF Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Recombinant Human EGF Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Recombinant Human EGF Revenue Market Share by Type (2019-2024)
Table 26. Global Recombinant Human EGF Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Recombinant Human EGF Revenue Market Share by Type (2025-2030)
Table 28. Global Recombinant Human EGF Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Recombinant Human EGF Revenue Market Share by Application (2019-2024)
Table 30. Global Recombinant Human EGF Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Recombinant Human EGF Revenue Market Share by Application (2025-2030)
Table 32. North America Recombinant Human EGF Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Recombinant Human EGF Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Recombinant Human EGF Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Recombinant Human EGF Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Recombinant Human EGF Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Recombinant Human EGF Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Recombinant Human EGF Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Recombinant Human EGF Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Recombinant Human EGF Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Recombinant Human EGF Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Recombinant Human EGF Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Recombinant Human EGF Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Recombinant Human EGF Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Recombinant Human EGF Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Recombinant Human EGF Market Size by Country (2025-2030) & (US$ Million)
Table 47. FUJIFILM Irvine Scientific Company Detail
Table 48. FUJIFILM Irvine Scientific Business Overview
Table 49. FUJIFILM Irvine Scientific Recombinant Human EGF Product
Table 50. FUJIFILM Irvine Scientific Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 51. FUJIFILM Irvine Scientific Recent Development
Table 52. PeproTech, Inc Company Detail
Table 53. PeproTech, Inc Business Overview
Table 54. PeproTech, Inc Recombinant Human EGF Product
Table 55. PeproTech, Inc Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 56. PeproTech, Inc Recent Development
Table 57. R&D Systems (Bio-Techne) Company Detail
Table 58. R&D Systems (Bio-Techne) Business Overview
Table 59. R&D Systems (Bio-Techne) Recombinant Human EGF Product
Table 60. R&D Systems (Bio-Techne) Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 61. R&D Systems (Bio-Techne) Recent Development
Table 62. Miltenyi Biotec Company Detail
Table 63. Miltenyi Biotec Business Overview
Table 64. Miltenyi Biotec Recombinant Human EGF Product
Table 65. Miltenyi Biotec Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 66. Miltenyi Biotec Recent Development
Table 67. Thermo Fisher Scientific Company Detail
Table 68. Thermo Fisher Scientific Business Overview
Table 69. Thermo Fisher Scientific Recombinant Human EGF Product
Table 70. Thermo Fisher Scientific Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 71. Thermo Fisher Scientific Recent Development
Table 72. Abcam PLC Company Detail
Table 73. Abcam PLC Business Overview
Table 74. Abcam PLC Recombinant Human EGF Product
Table 75. Abcam PLC Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 76. Abcam PLC Recent Development
Table 77. BioLegend Way Company Detail
Table 78. BioLegend Way Business Overview
Table 79. BioLegend Way Recombinant Human EGF Product
Table 80. BioLegend Way Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 81. BioLegend Way Recent Development
Table 82. STEMCELL Technologies Company Detail
Table 83. STEMCELL Technologies Business Overview
Table 84. STEMCELL Technologies Recombinant Human EGF Product
Table 85. STEMCELL Technologies Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 86. STEMCELL Technologies Recent Development
Table 87. Eurofins DiscoverX Company Detail
Table 88. Eurofins DiscoverX Business Overview
Table 89. Eurofins DiscoverX Recombinant Human EGF Product
Table 90. Eurofins DiscoverX Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 91. Eurofins DiscoverX Recent Development
Table 92. RayBiotech, Inc Company Detail
Table 93. RayBiotech, Inc Business Overview
Table 94. RayBiotech, Inc Recombinant Human EGF Product
Table 95. RayBiotech, Inc Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 96. RayBiotech, Inc Recent Development
Table 97. Prospec-Tany Company Detail
Table 98. Prospec-Tany Business Overview
Table 99. Prospec-Tany Recombinant Human EGF Product
Table 100. Prospec-Tany Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 101. Prospec-Tany Recent Development
Table 102. Tonbo Biosciences Company Detail
Table 103. Tonbo Biosciences Business Overview
Table 104. Tonbo Biosciences Recombinant Human EGF Product
Table 105. Tonbo Biosciences Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 106. Tonbo Biosciences Recent Development
Table 107. EnQuire Bio Company Detail
Table 108. EnQuire Bio Business Overview
Table 109. EnQuire Bio Recombinant Human EGF Product
Table 110. EnQuire Bio Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 111. EnQuire Bio Recent Development
Table 112. ScienCell Research Laboratories Company Detail
Table 113. ScienCell Research Laboratories Business Overview
Table 114. ScienCell Research Laboratories Recombinant Human EGF Product
Table 115. ScienCell Research Laboratories Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 116. ScienCell Research Laboratories Recent Development
Table 117. BioVision, Inc Company Detail
Table 118. BioVision, Inc Business Overview
Table 119. BioVision, Inc Recombinant Human EGF Product
Table 120. BioVision, Inc Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 121. BioVision, Inc Recent Development
Table 122. Abm Inc Company Detail
Table 123. Abm Inc Business Overview
Table 124. Abm Inc Recombinant Human EGF Product
Table 125. Abm Inc Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 126. Abm Inc Recent Development
Table 127. Cell Guidance Systems Company Detail
Table 128. Cell Guidance Systems Business Overview
Table 129. Cell Guidance Systems Recombinant Human EGF Product
Table 130. Cell Guidance Systems Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 131. Cell Guidance Systems Recent Development
Table 132. Creative BioMart Company Detail
Table 133. Creative BioMart Business Overview
Table 134. Creative BioMart Recombinant Human EGF Product
Table 135. Creative BioMart Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 136. Creative BioMart Recent Development
Table 137. Sino Biological Company Detail
Table 138. Sino Biological Business Overview
Table 139. Sino Biological Recombinant Human EGF Product
Table 140. Sino Biological Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 141. Sino Biological Recent Development
Table 142. Cell Sciences Company Detail
Table 143. Cell Sciences Business Overview
Table 144. Cell Sciences Recombinant Human EGF Product
Table 145. Cell Sciences Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 146. Cell Sciences Recent Development
Table 147. Axol Bioscience Company Detail
Table 148. Axol Bioscience Business Overview
Table 149. Axol Bioscience Recombinant Human EGF Product
Table 150. Axol Bioscience Revenue in Recombinant Human EGF Business (2019-2024) & (US$ Million)
Table 151. Axol Bioscience Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recombinant Human EGF Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Recombinant Human EGF Market Share by Type: 2023 VS 2030
Figure 3. ≥98% SDS-PAGE Features
Figure 4. 95%-98% SDS-PAGE Features
Figure 5. <95% SDS-PAGE Features
Figure 6. Global Recombinant Human EGF Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Recombinant Human EGF Market Share by Application: 2023 VS 2030
Figure 8. Scientific Research Case Studies
Figure 9. Medical Drug Case Studies
Figure 10. Others Case Studies
Figure 11. Recombinant Human EGF Report Years Considered
Figure 12. Global Recombinant Human EGF Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Recombinant Human EGF Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Recombinant Human EGF Market Share by Region: 2023 VS 2030
Figure 15. Global Recombinant Human EGF Market Share by Players in 2023
Figure 16. Global Top Recombinant Human EGF Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Human EGF as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Recombinant Human EGF Revenue in 2023
Figure 18. North America Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Recombinant Human EGF Market Share by Country (2019-2030)
Figure 20. United States Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Recombinant Human EGF Market Share by Country (2019-2030)
Figure 24. Germany Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Recombinant Human EGF Market Share by Region (2019-2030)
Figure 32. China Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Recombinant Human EGF Market Share by Country (2019-2030)
Figure 40. Mexico Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Recombinant Human EGF Market Share by Country (2019-2030)
Figure 44. Turkey Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Recombinant Human EGF Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. FUJIFILM Irvine Scientific Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 47. PeproTech, Inc Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 48. R&D Systems (Bio-Techne) Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 49. Miltenyi Biotec Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 50. Thermo Fisher Scientific Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 51. Abcam PLC Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 52. BioLegend Way Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 53. STEMCELL Technologies Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 54. Eurofins DiscoverX Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 55. RayBiotech, Inc Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 56. Prospec-Tany Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 57. Tonbo Biosciences Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 58. EnQuire Bio Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 59. ScienCell Research Laboratories Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 60. BioVision, Inc Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 61. Abm Inc Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 62. Cell Guidance Systems Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 63. Creative BioMart Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 64. Sino Biological Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 65. Cell Sciences Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 66. Axol Bioscience Revenue Growth Rate in Recombinant Human EGF Business (2019-2024)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
